Richard J Lee
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard J Lee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04824937 · Telaglenastat + Talazoparib In Prostate CancerMassachusetts General Hospital · withdrawn · Prostate Cancer Metastatic · principal investigator
- N/ANCT01961713 · Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing ProstatectomyMassachusetts General Hospital · recruiting · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 84 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A systems-level analysis of DNA damage and repair in senescence, aging and cancerR01AG090585 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · fiscal years 2026 · $723,962 awarded in 2026Same name and institution; not confirmed by an ID
- Cell Isolation and Cell Culture LaboratoryP01HL064858 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · fiscal years 2003 to 2005 · $249,206 awarded in 2005Same name and institution; not confirmed by an ID
- TRAINING GRANT IN CELLULAR AND MOLECULAR NEUROBIOLOGYT32NS007366 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · fiscal years 1995 to 2000 · $158,143 awarded in 2000Same name and institution; not confirmed by an ID
- MECHANISM OF ACTION OF DYNAMINR01GM026701 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · fiscal years 1985 to 1998 · $226,645 awarded in 1998Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:13 UTC. The ranking covers the 200 most relevant of 75 PubMed records, and a shared surname and initials can bring in a namesake. All 75 on PubMed
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med · 20116,168 citationsRCR 158.5
- Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl J Med · 20102,851 citationsRCR 65.3
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med · 20121,765 citationsRCR 46.2
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Nature · 20101,437 citationsRCR 31.5
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.N Engl J Med · 2012873 citationsRCR 21.8
- Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.J Clin Oncol · 2008473 citationsRCR 11.7
- T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection.J Clin Invest · 2012452 citationsRCR 15.4
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.J Clin Oncol · 2013309 citationsRCR 7.5
- 276 citationsRCR 11.1
- Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses.Heart · 2003240 citationsRCR 6.6